Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Jérôme RoncalliFrançois RoubilleYves CottinLionel LerouxAnthony MathurJohn IrvingSohail Q KhanNicolas MeneveauDidier BressonThomas HovasseGiulio PompilioAnthony MattaPhilippe HenonGuillaume TrebuchetMatthieu de KalbermattenIbon GaritaonandiaEric SalouxAlain ManriqueNicolas MeyerPierre-Yves MarieDeepak BhattScott D SolomonGilles MontalescotDavid E NewbyFaiez Zannad
• Organismes : Service Cardiologie [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires Module Biothérapies CHU Montpellier = Montpellier University Hospital Service de Cardiologie [CHU de Dijon] Département de cardiologie Barts Heart Centre [London, UK] Barts Health NHS Trust [London, UK] Ninewells Hospital and Medical School [Dundee] Queen Elizabeth Hospital University Hospitals Birmingham [Birmingham, Royaume-Uni] NHS Foundation Trust [London] Hôpital Jean Minjoz [Besançon] Centre Hospitalier Emile Muller [Mulhouse] Institut Cardiovasculaire Paris Sud Centro Cardiologico Monzino [Milano] Università degli Studi di Milano = University of Milano Service Cardiologie [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires Module Biothérapies CellProthera CellProthera CellProthera CellProthera Service de cardiologie et de pathologie vasculaire [CHU Caen] Service de médecine nucléaire [CHU Caen] Groupe Méthodes en Recherche Clinique [Strasbourg] Défaillance Cardiovasculaire Aiguë et Chronique Service de Médecine Nucléaire [CHRU Nancy] Nancyclotep- Experimental Imaging Platform = Plate-forme d'imagerie moléculaire Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai [New York] Brigham and Women's Hospital [Boston] Harvard Medical School [Boston] CHU Pitié-Salpêtrière [AP-HP] Groupe Action British Heart Foundation Centre of Research Excellence The University of Edinburgh Défaillance Cardiovasculaire Aiguë et Chronique Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] French-Clinical Research Infrastructure Network - F-CRIN [Paris]
• Publié dans JACC: Heart Failure le 29/10/2020

---

Fichiers liés : 1-s2.0-S2213177925005542-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Vincent GrégoireKévin QuintinFlorence HuguetPierre BoisselierUlrike SchickPhilippe GiraudLaure VieillevigneCyrus ChargariThomas LeroyYoann PointreauPierre Blanchard
• Organismes : Centre Léon Bérard [Lyon] Assistance publique - Hôpitaux de Paris (AP-HP) Sorbonne Université CHU Tenon [AP-HP] UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle Laboratoire de Traitement de l'Information Medicale Hôpital Européen Georges Pompidou [APHP] Université Paris Cité Institut Universitaire du Cancer de Toulouse - Oncopole Oncopole Claudius Regaud Assistance publique - Hôpitaux de Paris (AP-HP) Sorbonne Université Centre Jean Bernard [Institut Inter-régional de Cancérologie - Le Mans] Département de radiothérapie [Gustave Roussy] Institut Gustave Roussy Université Paris-Saclay
• Publié dans Cancer/Radiothérapie le 29/10/2020

---

Résumé : This article reviews the various exclusive or postoperative external radiotherapy and brachytherapy options for oropharyngeal squamous cell carcinoma. Dose levels, fractionation, and association with systemic treatments are presented. The need for neck node dissection following local treatment is discussed, as well as specificities for the management of p16-positive tumours. Guidelines for target volume selection and delineation are thoroughly elaborated.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Marianne DebueThibault GuinaldoDavid AyacheFrédéric BachevillerSarah BarbierLéa BerthomierEtienne BlotStephan ConseilPierre DanielWarren DanielEdmée DurandFlorian GibierStéphane GuevelFrank GuibertJean-Baptiste HernandezOlivier JaronArnold ManhavalAdrien MaussGilles MontesquieuCoralline NicolasPhilippe PalanyOlivier PeronIsabelle PfaffenzellerBruno PradelStéphane Saux-PicartAnastasiia TarasenkoBenoît ThoméThéo Tournier
• Organismes : Centre d’Etudes en Météorologie Satellitaire Centre d’Etudes en Météorologie Satellitaire Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Services Météorologiques de Météo-France Direction des Services Météorologiques de Météo-France Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction des Services Météorologiques de Météo-France Direction des Opérations pour la Prévision Direction des Services Météorologiques de Météo-France Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction Inter-Régionale des Antilles-Guyane Direction des Opérations pour la Prévision Direction des Opérations pour la Prévision Direction des Services Météorologiques de Météo-France Centre d’Etudes en Météorologie Satellitaire Institut Des Substances et Organismes de la Mer - UR 2160 Centre National d'Études Spatiales [Toulouse] Météo-France Direction des Services Météorologiques de Météo-France
• Publié dans La Météorologie le 02/11/2020

---

Résumé : Depuis 2011, des échouements massifs de sargasses ont lieu dans les Antilles françaises. Afin de limiter les conséquences néfastes engendrées lors de leur décomposition sur les plages, les plans de prévention et de lutte contre les sargasses ont identifié le besoin de mettre en place un dispositif de surveillance et de prévision des échouements en appui des institutions publiques. Cette prévision, développée et opérée à Météo-France depuis 2019, constitue un service public unique en Europe. Elle repose sur trois axes : la détection satellitaire des sargasses, la modélisation de leur dérive et la production de bulletins de risque d'échouement.

---

Fichiers liés : article_final.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Romain StammlerAlexandre ValléeJulien RohmerNathalie GrardelNoémie AbisrorWadih Abou ChahlaFélix AckermannAntoine BaudetNabil BelfekiRaouf Ben AbdelaliAudrey BidetJean-Sébastien BladéSéverine BleuseBernard BonnotteMohammed Azzedine BouderbalaJean-Michel CayuelaSafia ChebrekJérémie DionAntoine DossierNicolas DuployezStanislas FaguerPascale Flandrin-GrestaLionel GalicierCatherine GodonMaximilien GrallVincent JachietMathieu JouvrayMathieu JouvrayIrina LatuEmmanuel LedoultEtienne LenglineAmélie LeursLudovic LhermitteFrançois LifermannNicolas LimalBertrand LiogerMaxime LugosiIrène MachelartMickaël MartinNihal MartisLaurent MauvieuxSara Melboucy-BelkhirCatherine MohrGuillaume MoulisMarie Joelle MozicconacciDina NaguibAntoine NéelFranck NicoliniRoderau OuthKewin PanelClaude PreudhommeMathieu PuyadeThomas QuemeneurViviane Queyrel MoranneJérôme ReyPhilippe RousselotNicolas SchleinitzBorhane SlamaDelphine Staumont-SalléCamille TailléLouis TerriouLudovic TrefondJean-François ViallardJean-Emmanuel KahnGuillaume LefèvreMatthieu GrohSébastien AbadHenri Abi RachedAmir AdedjoumaDidier AdikoChristian AgardKais AhmadNuri AhwijJean-Christophe AlloZineb AmraniAchille AoubaHélène AubertNathalie BaizeAndré BaruchelCaroline BealIssam BelhajMaxime BembaAlice BerezneClément BeuvonMarie Beylot BarryOdile Beyne RauryPhilip BielefeldConstance BlandinMario BoisseauCaroline BonmatiCécile BorelDaoud BouredjiHélène BoutrouxAnne BrignierBenoit BrihayeMarc BrouillardThomas BrunetClaude-Eric BulaboisFrance CamposMartin CarrePascal CathébrasEmilie CayssialsÉmilie ChalayerCécile ChenivesseJean‐claude ChomelValérie CoiteuxThibaut ComontAdrien ContejeanVincent CottinAmélie Couteau ChardonPriscille CoutureYoann CrabolGwenvael DanicAdrien DanielStéphane DarreSebastien de AlmeidaAdèle de MassonEric DelabesseThomas DelayeFréderic DezoteuxViviane DubruilleClairelyne DupinMylène DuplanCécile Audrey DurelMikaël EbboJaphete Darline Elenga KoengaAberrazak El YamaniAlexandra EspitiaPascaline EtancelinGabriel EtienneNicolas EtienneMarine EustachePhilippe EvonOlivier FainSophie Georgin LavialleBertrand GodeauCécile GoldenTiphaine GoulenokClément GourguechonCarine GreibAurélien GuffroyPhilippe GuilpainEmmanuel GyanÉric HachullaMarion HermetFrançoise HuguetLucas InchiappaIbrahim JdidElisa JolyKatayoun JondeauMorgane JoubertAnne JourdainGalith KalmiBrigitte LagrangeJudith Landman-ParkerMathilde Le BrunNoémie Le GouellecCaroline LejeuneSarah Le NaourMathilde LeclercqPaul LegendreClaire Le PenduFaustine LhommeOlivier LidoveElena LopinetPierre LozachAurélie MadelonLéa MairotFréderic MaloiselAnne MarfaingVictor MargelidonIbrahim MarrounAgathe MasseauFrançois MaurierArsène MekinianMathieu MeunierMarc MichelChafika Morati-HafsaouiMarjolaine MorgandEmilie MullerThierry MuronAlexandre NguyenHubert NiellyMario OjedaThomas PapoRomain PauleArnaud PetitJean Michel PignonCamille Prot-LeurentJérome RazanamaherySabine RevuzSophie RigaudeauÉtienne RivièreCédric RossiManon RoucoulesJean-Philippe RougierMathilde RoumierBenedicte RouvièreFrédéric Roy PeaudArnaud Saint LezerLaurent SaillerGaetan SauvetreLéa SaveyQuentin ScanvionLaurent SchwarbDamien SèneLaurence SimonBohrane SlamaMicha SrourFelipe SuarezBenjamin SubranSuzanne TavitianColas TcherakianNathalie TieulieJose Miguel TorregrosaElise ToussaintJulie TrichereauRémi VatanGael VaudourAlexandre VlakosSorin VisanicaLaurent VoilatFanny VuottoStéphanie WaninHacène ZerazhiJean Marc ZiniStéphane Zographos
• Organismes : Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Hôpital Foch [Suresnes] Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Sorbonne Université Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre Hospitalier d'Annecy Genevois Groupe Hospitalier Sud Ile-de-France Laboratoire CERBA [Saint Ouen l'Aumône] CHU de Bordeaux Pellegrin [Bordeaux] Hopital d'instruction des armées Sainte-Anne [Toulon] Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Service Hématologie - IUCT-Oncopole [CHU Toulouse] Service Médecine interne et immunopathologie clinique [CHU Toulouse] Département de Néphrologie et Transplantation d'organes [CHU Toulouse] Institut des Maladies Métaboliques et Casdiovasculaires Service Médecine interne [CHU Toulouse] Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Centre Hospitalier Régional Universitaire [CHU Lille] Institute for Translational Research in Inflammation - U 1286 Centre de Référence National des Syndromes Hyperéosinophiliques - Centre of Reference for Hypereosinophilic Syndromes - Hôpital Foch Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Infection et inflammation Centre de Recherches en Cancérologie de Toulouse Laboratoire Hématologie - IFB [CHU Toulouse] Laboratoire Hématologie - Rangueil [CHU Toulouse] Service Hématologie - IUCT-Oncopole [CHU Toulouse]
• Publié dans Journal of Allergy and Clinical Immunology: In Practice le 27/10/2020

---

Résumé : The FIP1L1-PDFGRA (F/P)-associated hypereosinophilic syndrome (HES) is a rare condition. The F/P fusion gene testing is one of the first-line investigations in patients with unexplained eosinophilia and yields poor diagnostic performance. OBJECTIVE: To build and validate the factor interacting with PAPOLA and CPSF1 (FIP) score: a set of weighted criteria warranting testing for the F/P fusion gene. METHODS: We merged data from 151 patients with F/Passociated HES and 320 patients with either F/P-negative HES (n = 279) or hypereosinophilia of undetermined significance (n = 41). Training and validation cohorts (comprising, respectively, 90% and 10% of all patients) were randomly dichotomized. Variables with a P value less than .20 in univariate analysis were included in the multivariable forward-backward logistic regression model to assess their independent contribution to testing positive for the F/P fusion gene. Beta coefficients from multivariable logistic regression were used to assign points for the construction of the score. RESULTS: Age younger than 66 years, male sex, splenomegaly, lymphomatoid papulosis, absence of gastrointestinal involvement, high serum vitamin B 12 , high serum tryptase, and normal serum immunoglobulin E levels were the 8 variables retained in the model. The best cutoff value was greater than 48. The model yielded a sensitivity, specificity, positive predictive value, negative predictive value, and area under the curve, respectively, of 88.3%, 93.7%, 87.1%, 94.4%, and 0.962 in the training dataset and of 85.7%, 97.0%, 85.7%, and 97.0%, 0.986 in the validation dataset. CONCLUSIONS: The FIP score highlights the need for closely selecting patients with hypereosinophilia for whom F/P fusion gene testing should be performed, resulting in medical time reduction and substantial cost-savings.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Pierre-André LafonLaurent PrézeauJean-Philippe PinPhilippe Rondard
• Organismes : Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle Institut de Génomique Fonctionnelle
• Publié dans Trends in Pharmacological Sciences le 25/10/2020

---

Résumé : Camelid-derived nanobodies offer a promising alternative to conventional antibodies for the treatment of brain disorders. Their current development in models of schizophrenia or Alzheimer's disease highlights their strong therapeutic potential. Optimizing their delivery and ensuring their safety are major challenges, but their modularity and low immunogenicity make them promising candidates for neurotherapy.

---

Fichiers liés : Lafon et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Philippe RyvlinMargaux HuotLuc ValtonLouis MaillardFabrice BartolomeiPhilippe DerambureEdouard HirschVéronique MichelFrancine ChassouxJérôme PetitArielle CrespelArnaud BirabenVincent NavarroPhilippe KahaneBertrand de ToffolPierre ThomasSarah RosenbergAdriano BerniniAnne-Laure CharloisLaura CraciunFatima ChorfaPauline DucouretAxel FerreiraMathilde LeclercqManon MartyBlanca Mercedes AlvarezMilena SampaioAntoine SpahrNoémie Timestit-KurlandMaylis TouyaPascal RoySylvain Rheims
• Organismes : Centre Thématique de Recherche et de Soins - Institut des Épilepsies de l'Enfant et de l'Adolescent = IDEE Epilepsy Institute Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Centre de recherche cerveau et cognition Centre Hospitalier Universitaire de Toulouse Ingénierie Moléculaire, Cellulaire et Physiopathologie Service de neurologie [CHRU Nancy] Institut de Neurosciences des Systèmes Service d'Epileptologie et de Rythmologie Cérébrale [Hôpital de la Timone, AP-HM] Service de neurophysiologie clinique Pharmacologie de la mort neuronale et de la plasticité cérébrale Centre de référence des épilepsies rares [CHU Strasbourg] Service de Neurologie [Strasbourg] Service de neurologie [Bordeaux] Service de neurochirurgie [AP-HP Hôpital Lariboisière] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Centre Médical de la Teppe Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute [GIN] Grenoble Institut des Neurosciences CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Régional Universitaire de Tours Inserm U930 Imagerie et Cerveau Service de Neurologie [CHU Nice] Service Neurologie [CHU Clermont-Ferrand] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Hospital General Universitario "Gregorio Marañón" [Madrid] Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service du sommeil, de l'épilepsie et de neurophysiologie pédiatrique clinique [Hospices Civils de Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
• Publié dans The Lancet Neurology le 27/10/2020

---

Résumé : Background Novel biomarkers of the risk of sudden unexpected death in epilepsy (SUDEP) are needed to better inform people with epilepsy of their individual risk and identify those at a high risk. The aim of this study was to identify such biomarkers, particularly with the exploration of seizures characteristics that have not been previously investigated, including peri-ictal peripheral oxygen saturation (SpO2) and site of seizure onset. Methods We conducted a nested case–control study of SUDEP within a dedicated nationwide prospective cohort. Eligible participants were adults with drug-resistant focal epilepsy undergoing in-hospital seizure monitoring at 16 epilepsy monitoring units in France. Clinical data, results from presurgical investigations, and raw recordings from video EEG, electrocardiogram (ECG), and SpO2 were collected until the end of the recruitment period. The French National Directory of Natural Persons Identification was queried annually to identify deaths. SUDEP cases were adjudicated on the basis of medical records and interviews documenting the circumstances of death. Each SUDEP case was matched to four controls on the basis of study centre and date of inclusion. SUDEP risk factors were identified using LASSO-penalised conditional logistic regression. Findings From May 18, 2010, to Aug 23, 2015, we enrolled a total of 1074 participants and followed their vital status until the end of 2018, yielding a total of 6828 patient-years of follow-up. 42 participants died during follow-up, including 18 cases of definite or probable SUDEP, resulting in a SUDEP rate of 2·64/1000 patient-years (95% CI 1·36–3·92). Four risk factors were significantly associated with the risk of SUDEP: an extratemporal epileptogenic zone (OR 37·8, 95% CI 3·21–446·2, p=0·0039), a BMI of 30 or higher (26·0, 2·0–339·6, p=0·013), male sex (12·6, 1·5–106·8, p=0·0201), and predominantly nocturnal seizures (6·0, 1·2–28·7, p=0·026). In contrast, the presence of peri-ictal SpO2 of less than 80% during focal seizures, the frequency of focal-to-bilateral tonic–clonic seizures, heart rate variability, age at epilepsy onset, number of antiseizure medications, and history of depression were not significantly associated with SUDEP. Interpretation Extratemporal epilepsies involving the perisylvian region or frontal lobe appear to be associated with an increased risk of SUDEP. This finding warrants confirmation in larger cohorts and underscores the need to improve the diagnosis and surgical management of extratemporal epilepsies, which might contribute to improved SUDEP risk stratification and prevention.

---

Fichiers liés : 1-s2.0-S1474442225003795-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2025
• Auteurs : Gaspard SucJulien DreyfusJulien TernacleThierry Le TourneauPhilippe DemersLinrui GuoAngel Yi Nam FuJean Claude DibMohammad Al FadhalahThays SokolovAmedeo AnselmiDidier TchétchéOphélie Brault MeslinAnge GoutondjiYoan Lavie-BadiePatrick SeknadjiAugustin CoisneDimitri ArangalageAnne BernardUsha ManianMalek KassAntonio FioreArnaud MaudiereYohann BohbotAurélien SeemannNadjib HammoudiLoïc BièrePierre-Yves LerouxJessica ForcilloAntoine JeuMohammed NejjariOlivier HuttinMartine GilardClaire BouletiDavid HarnettJean-Francois LegareThiziri Si MoussiJian YeCatherine SportouchBindu BittiraLaura MunteFabrice BauerHoward Leong-PoiAli Fatehi HassanabadThomas ModineJordan BernickGeorge WellsRoja GaudaBernard IungWilliam KentMichael W.A. ChuDenis BouchardJean-François ObadiaDavid Messika-Zeitoun
• Organismes : University of Ottawa Heart Institute Centre cardiologique du Nord CHU de Bordeaux Pellegrin [Bordeaux] Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 Montreal Heart Institute - Institut de Cardiologie de Montréal Western University [Ontario] University of Ottawa Heart Institute Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada] Hospices Civils de Lyon Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Laboratoire Traitement du Signal et de l'Image Clinique Pasteur [Toulouse] Institut Mutualiste de Montsouris Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Universitaire de Toulouse Hôpital Privé Jacques Cartier [Massy] Centre Hospitalier Régional Universitaire [CHU Lille] Cardiovascular Research Foundation [New York, NY, USA] Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 Institut Pasteur de Lille Laboratoire de Recherche Vasculaire Translationnelle Institut de neurophysiopathologie Hôpital Henri Mondor CHU Marseille Cardiologie [CHU Amiens] Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 CHU Pitié-Salpêtrière [AP-HP] University of Ottawa Heart Institute Montreal Heart Institute - Institut de Cardiologie de Montréal Hospices Civils de Lyon University of Ottawa Heart Institute
• Publié dans Canadian Journal of Cardiology le 01/11/2020

---

Résumé : Background Calcified mitral valve disease (CMVD) is an increasingly recognized condition associated with specific management challenges. MITRACURE, a large multicenter observational registry conducted in France and Canada, provides real-world insights into the characteristics and outcomes of patients with CMVD undergoing MV surgery. Methods Among the 3,522 patients included in MITRACURE, patients identified with CMVD were matched 4:1 for age, sex, and concomitant procedures with patients with myxomatous MV disease. Results Sixty patients (2%) with CMVD were matched to 240 with myxomatous MV disease. Compared to the myxomatous cohort, CMVD patients had a greater burden of cardiovascular risk-factors, more comorbidities, and a more advanced presentation, with 70% vs. 52% in NYHA class III–IV (P=0.01). In-hospital mortality and major complication rates (composite of death, cardiogenic shock/low cardiac output requiring inotropes, acute renal failure requiring dialysis, and stroke or transient ischemic attack) were significantly higher in CMVD than myxomatous patients (20% vs. 4%, and 38% vs. 20%, both P<0.01). Median EuroSCORE II was slightly higher in CMVD patients (3.5 [IQR 2.2-5.7]) compared with those with myxomatous disease (2.6 [IQR 1.5-4.2], P<0.01). However, the observed mortality in the CMVD group was three to four times higher than predicted, whereas in the myxomatous group it was consistent with predicted values. Conclusion CMVD defines a high-risk surgical population with substantial baseline cardiovascular morbidity and markedly elevated postoperative mortality and complication rates that were substantially underestimated by EuroSCORE II emphasizing the need for refined risk prediction models and individualized management strategies in this subset of patients.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/10/2025
• Auteurs : Boris JungMathieu JabaudonAudrey de JongLaurent laurent-bitker BitkerJules AudardKada KloucheBenjamine SartonChristophe GuittonSigismond LasockiBenjamin RieuEmmanuel CanetCaroline JeantrelleAntoine RoquillyJulien MayauxFranck VerdonkJulien PottecherMartine FerrandiereBeatrice RiuPierre GarconMona AssefiPhilippe DetoucheJean Marie ForelClaire Penetrat-RogerJeremy BourenneSophie JacquierDavid BougonAmelie RollePhilippe CorneNacim BenchabaneJean Christophe RichardKarim AsehnouneGerald ChanquesJean-Baptiste LascarrouFoud BelafiaMaxime FossetHelena HuguetEmmanuel FutierNicolas MolinariSamir JaberSonia MachadoVincent BrunotLaura PlatonDelphine DaubinNoémie BesnardValérie MoulaireCorinne PelleLiliane LandreauGuillaume DeneilHodane YonisMehdi MezidiLouis ChauvelotS. SilvaPatrice TirotCedric DarreauNicolas ChudeauMaeva CampfortSoizic GergaudLoris GiordanettoThomas GodetJean-Baptiste LascarrouJean-Baptiste LascarrouMikahel GiabicaniKarim AshenouneYannick HourmantAlexre BourdiolCécile PoulainAlexre DemouleMartin DresMaxens DecavèleMarie LecronierCôme BureauJulien Do ValeSophie MenatSebastien ClercJeremie PichonJennifer CatanoAdam CelierValentine Le StangMarie-Claire DiemozHugo Flis-RichardEmmanuel PardoNatacha KapandjiAlain MeyerStephane HecketsweilerPaer Selim AbbackLy van Phach VongDelphine ReitterJonathan ZarkaJean Michel ConstantinFlorence DavietLaurent MullerJean Yves LefrantStephan EhrmannCharlotte Salmon GinniereLaëtitia Bodet-ContentinJulien CarvelliMarc GainierBernard CholleyJean DellamonicaMathieu JozwiakClement SacchieriAlexandre LautretteMartin CourLaurent ArgaudThomas RimmeleSebastien PreauXavier CapdevilaMaud FiancetteDamien RouxJulien BohePierre AsfarRussel ChabanneNicolas TerziNaïke BigeAude GarneroDjamel MokartHatem Kallel
• Organismes : Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire de Nîmes Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier]
• Publié dans JAMA Cardiology le 25/10/2020

---

Résumé : Importance The effect of sodium bicarbonate infusion on outcome in patients with severe metabolic acidemia and moderate to severe acute kidney injury is unknown. Objective To determine whether sodium bicarbonate infusion is associated with day 90 all-cause mortality in patients with severe metabolic acidemia and moderate to severe acute kidney injury. Design, Setting, and Participants Randomized, open-label, clinical trial conducted with 640 patients in 43 French intensive care units from October 6, 2019, to December 19, 2023, with 90-day follow-up. The last date of follow-up was June 17, 2024. Adults with severe metabolic acidemia (defined as pH ≤7.20) and moderate to severe acute kidney injury were enrolled. Intervention Patients were randomized 1:1 to receive either intravenous sodium bicarbonate infusion or no sodium bicarbonate to target an arterial pH of 7.30 or higher. Main Outcomes and Measures The primary outcome was day 90 all-cause mortality. Secondary outcomes included day 28 and day 180 all-cause mortality; use of organ support therapy, vasopressors, or invasive mechanical ventilation; intensive care unit and hospital length of stay; intensive care unit–acquired infections; fluid balance; day-7 Sequential [Sepsis-related] Organ Failure Assessment score (6 organ systems’ function is evaluated and scored from 0 [no dysfunction] to 4 [failure]; total score ranges from 0 [normal] to 24 [maximum failure]); and major adverse kidney events on day 90. Results Among 640 randomly assigned patients, 627 were analyzed (313 in the control group and 314 in the bicarbonate group). The median age was 67 years (IQR, 59-74 years); 194 of 314 patients (62%) in the bicarbonate group and 185 of 313 controls (59%) were male. In the primary analysis, day 90 all-cause mortality was 195 of 314 patients (62.1%) in the bicarbonate group and 193 of 313 (61.7%) in the control group (absolute difference, 0.4; 95% CI, −7.2 to 8.0; P = .91). There was no evidence of a group effect on day 28 or day 180 all-cause mortality. Among 18 secondary outcomes, kidney replacement therapy was used in 109 of 314 (35%) bicarbonate group patients and 157 of 313 (50%) controls (absolute difference, −15.5; 95% CI, −23.1 to −7.8). No evidence of a group effect was found on other secondary outcomes, including adverse events. Conclusions and Relevance For patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not affect mortality. Trial Registration ClinicalTrials.gov Identifier: NCT04010630

---

Fichiers liés : 2025 Jung et al.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/10/2025
• Auteurs : Jonas VanardoisPierre TrapPhilippe GoncalvesRoger FrançoisePierre LanariFrancesca PiccoliDidier MarquerJean-Louis PaquetteJérémie Melleton
• Organismes : Laboratoire Chrono-environnement (UMR 6249) Université de Lausanne = University of Lausanne Laboratoire Chrono-environnement (UMR 6249) Laboratoire Chrono-environnement (UMR 6249) Géosciences Montpellier Université de Lausanne = University of Lausanne Universität Bern = University of Bern = Université de Berne Universität Bern = University of Bern = Université de Berne Laboratoire Magmas et Volcans Laboratoire Magmas et Volcans Bureau de Recherches Géologiques et Minières
• Publié dans Bulletin de la Société Géologique de France le 28/10/2020

---

Résumé : This study investigates the P-T-t-D evolution of two metapelitic samples from the middle crust exposed in the Aiguilles Rouges Massif. Garnet compositional mapping, phase equilibrium modelling, zirconium-in-rutile thermometry, trace element geochemistry of garnet and monazite, and U-Pb LA-ICP-MS dating on monazite were used to better understand the tectonic and thermal history of the variscan External Crystalline Massifs. In the sample representing the upper-middle crust (AR736, southwestern part of the massif), using the preserved mineral assemblage in garnet inclusion

and garnet compositions, the prograde P-T path was constrained from ∼0.5-0.6 GPa and 550-625 °C to ∼0.76-0.82 GPa and 600-640 °C. The P-T conditions at the onset of this prograde evolution suggest a high geothermal gradient (∼30-35 °C/km) prior to the onset of crustal thickening. In the sample representing the lower-middle crust (AR14, central part of the massif), using the preserved mineral assemblage in garnet inclusion

, the occurrence of sillimanite and ilmenite in the matrix and garnet compositions, a b-shaped P-T path characterised by a late temperature increase during exhumation was identified. Both samples recorded a retrograde P-T stage at ∼0.4 GPa and 545 °C, dated at 315-305 Ma. Microstructural analysis indicates dextral transcurrent deformation from the late crustal thickening stage to the exhumation phase. Comparison with previously published P-T paths from eclogitic lenses highlights the juxtaposition of middle and lower crustal domains during dextral transcurrent deformation. We propose a tectonic model in which the formation of supra-subduction volcano-sedimentary basins (∼350 Ma) is followed by crustal thickening between 350 and 340 Ma under a thermal gradient of ∼5-15 °C/km. The exhumation of the lower and middle crust took place in a transcurrent regime between 340 and 305 Ma. This prolonged transcurrent tectonic activity suggests that the numerous transcurrent shear zones in the Variscan belt are not merely late orogenic structures but played a significant role in the geodynamic evolution, particularly in the exhumation of the orogenic crust, from the end of continental collision to the closure of the Variscan orogeny.

---

Fichiers liés : bsgf230022.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/10/2025
• Auteurs : Nathalie DemaureJehanne Le CunffMaryline DuchêneBertrand RozecFabien EspitalierJean-Michel CabonJean-Ferréol OilleauPhilippe GuerciFrançois LabasteOsama Abou-ArabPierre-Grégoire GuinotPierre DuvalEmmanuel BesnierErwan FlécherIsabelle LeroyerJeff MorcetClaire Fougerou-LeurentAlexandre MansourNicolas Nesseler
• Organismes : Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Service d'anesthésie et réanimation chirurgicale [Nantes] ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Régional Universitaire de Tours CHRU Brest - Département d'Anesthésie Réanimation CHRU Brest - Département d'Anesthésie Réanimation Service d'Anesthésie et Réanimation [CHRU Nancy] Pôle Anesthésie Réanimation [CHU de Toulouse] CHU Amiens-Picardie Université Marie et Louis Pasteur Service d'Anesthésie et Soins intensifs [CHU Rouen] Service d'Anesthésie et Soins intensifs [CHU Rouen] Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Université de Rennes Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Nutrition, Métabolismes et Cancer Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Nutrition, Métabolismes et Cancer
• Publié dans BMJ Open le 26/10/2020

---

Résumé : Introduction Postoperative pulmonary complications (PPCs) are common after cardiac surgery and are associated with significant morbidity and mortality. Lung-protective ventilation strategies have been proposed to reduce PPCs, but the optimal level of positive end-expiratory pressure (PEEP) and the use of alveolar recruitment manoeuvres (RMs) remain controversial. Methods/analysis In this investigator-initiated, multicentre, open, randomised, parallel-group, superiority clinical trial, elective cardiac surgery patients at risk of PPCs will be assigned to one of two intraoperative ventilation strategies: (1) an open-lung ventilation strategy with protective ventilation, moderate PEEP and RMs or (2) a standard protective ventilation with low PEEP and no RM. The primary outcome will be a composite of prolonged (>24 hour) postoperative mechanical ventilation, reintubation for any cause or hospital-acquired pneumonia within 7 days of surgery, or death within 28 days of surgery. Data will be analysed on an intention-to-treat basis. Ethics and dissemination The VACARM (impact of intraoperatiVe moderAte positive end-expiratory pressure with reCruitment mAnoeuvres versus low positive end-expiRatory pressure on major postoperative pulMonary complications and death after on-pump cardiac surgery in high-risk patients) trial has been approved by an independent ethics committee for all study centres. Recruitment began in July 2021. Results will be published in international peer-reviewed medical journals. Trial registration number ClinicalTrials.gov NCT04408495 .

---

Fichiers liés : e104179.full.pdf

---

Source